Johnson & Johnson (JNJ)

Johnson & Johnson offers stability and limited downside risk, making it a solid investment in volatile markets, despite not being a high-growth stock. The company's fiscal 2024 results showed moderate...

JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Tremfya. We do not expect any improvement in MedTech sales.

President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told...

The Company spend billions to produce 100% of its key medicines for Americans in the U.S.

Microsoft (MSFT -2.33%) and Johnson & Johnson (JNJ -1.64%) are leading companies in their respective industries. They both have impressive track records and have made their long-term shareholders sign...

Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key m...

Stock market sell-offs like the one we're currently experiencing are challenging periods for investors. However, with every challenge comes an opportunity to improve.

European stocks soared on Thursday after U.S. President Donald Trump's jarring about-turn on most tariffs. Tensions between Washington and Beijing remain high, however, with Trump ratcheting up duties...

Long before the S&P 500 became Wall Street's benchmark index, the iconic Dow Jones Industrial Average (^DJI 7.87%) was viewed as the best barometer of the stock market's health. Since its inception in...